Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Loss of Regulatory Enzyme Spurs Kidney Cancer Growth

By BiotechDaily International staff writers
Posted on 31 Jul 2014
Image: A metabolic enzyme has an unexpected role in regulating gene expression in kidney cancer. Primary human kidney tissue: FBP1 protein (green); cell nuclei (blue) (Photo courtesy of the University of Pennsylvania).
Image: A metabolic enzyme has an unexpected role in regulating gene expression in kidney cancer. Primary human kidney tissue: FBP1 protein (green); cell nuclei (blue) (Photo courtesy of the University of Pennsylvania).
Cancer researchers have found that the enzyme fructose-1,6-bisphosphatase 1 (FBP1) is missing or inactive in the clear cell renal cell carcinoma (ccRCC) form of kidney cancer, a lack that gives the cancer cells a metabolic advantage over surrounding normal tissue.

FBP1 is a gluconeogenesis regulatory enzyme that catalyzes the hydrolysis of fructose1,6-bisphosphate to fructose 6-phosphate and inorganic phosphate. Fructose-1,6-diphosphatase deficiency is associated with hypoglycemia and metabolic acidosis.

Investigators at the University of Pennsylvania (Philadelphia, USA) have been working with a mouse ccRCC model. Previous studies had shown that kidney tumors of this type were characterized by elevated glycogen levels and fat deposition. Development of these characteristics was associated with elevated expression of hypoxia inducible factors (HIFs) and mutations in the von Hippel-Lindau (VHL) encoded protein, pVHL, which occurs in 90% of ccRCC tumors.

The VHL protein (pVHL) is involved in the regulation of hypoxia inducible factor 1 alpha (HIF1alpha). This is a subunit of a heterodimeric transcription factor that at normal cellular oxygen levels is highly regulated. Under normal physiological conditions, pVHL recognizes and binds to HIF1alpha only when oxygen is present due to the post translational hydroxylation of two proline residues within the HIF1alpha protein. pVHL is an E3 ligase that ubiquitinates HIF1alpha and causes its degradation by the proteasome. In low oxygen conditions or in cases of VHL disease where the VHL gene is mutated, pVHL does not bind to HIF1alpha. This allows the subunit to dimerize with HIF1beta and activate the transcription of a number of genes, including vascular endothelial growth factor, platelet-derived growth factor B, erythropoietin, and genes involved in glucose uptake and metabolism.

In the current study, which was published in the July 20, 2014, online edition of the journal Nature, the investigators used an integrative approach comprising metabolomic profiling and metabolic gene set analysis to examine more than 600 kidney tumors from human patients. They determined that FBP1 was uniformly depleted in all of the ccRCC tumors examined. The human FBP1 locus was found to reside on chromosome 9q22, the loss of which was associated with poor prognosis for ccRCC patients.

FBP1 was found in the nucleus of normal cells, where it bound to HIF to modulate its effects on tumor growth. In cells lacking FBPI, rapidly growing tumor cells were found to produce energy up to 200 times faster than normal cells.

“This study is the first stop in this line of research for coming up with a personalized approach for people with clear cell renal cell carcinoma-related mutations,” said senior author Dr. Celeste Simon, professor of cell and developmental biology at the University of Pennsylvania. “Since FBP1 activity is also lost in liver cancer, which is quite prevalent, FBP1 depletion may be generally applicable to a number of human cancers.”

Related Links:
University of Pennsylvania


Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.